Our stance on:
Our guidance on the risk assessment and reduction of heart disease and strokes, including lipid modification, is based on the overwhelming body of evidence supporting the use of statins, even in people at relatively low risk.
The NICE guideline does not impose statins on everyone with a 10% or greater risk of developing heart disease or having a stroke within 10 years; it recognises the importance of personal choice in determining what measures are appropriate for preventing these. Our guidance says that due to a drop in the price of statins, these drugs are now cost effective at a lower clinical threshold. Decisions about whether patients should start or continue statin treatment should be made by the patient with their doctor.
The effectiveness of statins is now well proven, as is their
Hormone replacement therapy (HRT)
The NICE guideline on menopause recommends hormone replacement therapy (HRT) as an effective option for treating menopause symptoms including hot flushes and night sweats. The decision on whether or not to take HRT or any other treatment depends entirely on the individual woman’s circumstances and the discussion with her doctor or nurse.
The guideline clarifies the facts about the benefits and risks of taking HRT based on a thorough assessment of the evidence available. Individuals’ risks of specific outcomes will vary according to factors other than
We recommend that menopausal women discuss with their doctors their own individual situation in relation to the clarified risks and benefits to that they can
Cancer Drugs Fund (CDF)
Our approach to assessing the value of new cancer drugs has been reviewed on a regular basis since we were set up in 1999. The changes we made in response to the CDF reforms will help deliver faster access to effective cancer treatments.
For the first time, we are able to give patients access to a promising new cancer treatment whilst more evidence is gathered on its effectiveness. Where the case for routine use is not clear cut and more evidence
The new process can work well where companies work with NICE to price their drug
Contact the press office
0300 323 0142
This number is for journalist use only. Other members of the public please use 0300 323 0140 or firstname.lastname@example.org
Office hours: Mon - Fri,
Rebecca Smith - Head of Media
Phil Ranson - Media Relations Manager
Liz Adelanwa - Digital Media Manager
Jay Stone - Digital Media Manager
Trish Regis - Media Relations Executive
Emily Carey - Content Producer
Frequently Asked Questions
About NICE and our guidance
The National Institute for Clinical Excellence was set up in 1999. It then merged with the Health Development Agency in 2005 and changed its name to the National Institute for Health and Clinical Excellence.
Guidance topics are referred to us by NHS England and the Department of Health.
NICE guidance is developed by independent committees of experts. It may be a standing committee working on many guideline topics, or a topic-specific committee put together to work on a specific guideline.
Each our guidance programmes has its own process for developing guidance. Find out more about our guidance programmes here
All NICE committees include topic experts and
NICE technology appraisal decisions are the only legally-binding, mandatory recommendations NICE produces. These apply to drugs available on the NHS. The rest of the guidance NICE publishes aims to support decisions made by staff working in the health and social care sector. It is not mandatory.
All NICE guidance is regularly
About our guidance on drugs
NICE technology appraisals
The cost of the drug being appraised is just one thing the NICE committee considers. Costs will always be assessed alongside how effective the treatment is.
The NHS should make the drug available within 3 months of the NICE guidance being issued unless there is an alternative market access agreement from NHS England.
All NICE guidance is regularly
From 1 March 2000 to 30 June 2016, NICE published 239 single technology
The Cancer Drugs Fund (CDF) was set up by the Government in 2011 for people in England to access cancer drugs that were not routinely available on the NHS. NICE began to reappraise all drugs currently in the CDF in July 2016